Review



vegf a 165 b assay  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems vegf a 165 b assay
    Vegf A 165 B Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Human+VEGF+165b+DuoSet+ELISA/pmc12133783-77-5-10
    Average 93 stars, based on 24 article reviews
    vegf a 165 b assay - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms
    Article Snippet: VEGF xxx b was determined with a similar sandwich ELISA (R&D Systems Cat. No. MAB3045). .. For the VEGF xxx b ELISA, the capture antibody was a monoclonal biotinylated mouse anti-human antibody raised against the terminal nine amino acids of VEGF 165 b (R&D Systems); a standard curve for this assay was built with recombinant human VEGF 165 b (R&D Systems). ..

    Article Title: Expression of Total Vascular Endothelial Growth Factor and the Anti-angiogenic VEGF 165 b Isoform in the Vitreous of Patients with Retinopathy of Prematurity
    Article Snippet: .. Total VEGF and VEGF 165 b were measured in vitreous samples by enzyme-linked immunosorbent assay (ELISA) using a kit for human anti-VEGF (all isoforms) (Duoset VEGF ELISA DY-293; R and D Systems) and a kit for human VEGF 165 b (Duoset VEGF ELISA DY3045; R and D Systems). ..

    Recombinant:

    Article Title: Borrelidin modulates the alternative splicing of VEGF in favour of anti-angiogenic isoforms
    Article Snippet: VEGF xxx b was determined with a similar sandwich ELISA (R&D Systems Cat. No. MAB3045). .. For the VEGF xxx b ELISA, the capture antibody was a monoclonal biotinylated mouse anti-human antibody raised against the terminal nine amino acids of VEGF 165 b (R&D Systems); a standard curve for this assay was built with recombinant human VEGF 165 b (R&D Systems). ..

    Article Title: Overexpression of VEGF 165 b in Podocytes Reduces Glomerular Permeability
    Article Snippet: .. After blocking with 100 μl of 5% BSA in PBS for 1 hour at 37°C, 100 μl of recombinant human VEGF 165 b (R&D Systems) diluted in 1% BSA in PBS (ranging from 62.5 pg/ml to 4.0 ng/ml) or protein samples was added to each well. .. After incubation for 1 hour at 37°C with shaking and three washes, 100 μl of mouse monoclonal anti-VEGF xxx b biotinylated IgG (clone 264610/1; R&D Systems) at 0.4 μg/ml was added to each well, and the plate was left for 1 hour at 37°C with shaking.

    Article Title: Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
    Article Snippet: .. VEGF xxx b was determined with a similar sandwich ELISA, using for detection a monoclonal biotinylated mouse anti-human antibody raised against the terminal nine amino acids of VEGF 165 b (R&D Systems; clone 264610/1), and a standard curve for this assay was built with recombinant human VEGF 165 b (R&D Systems) ( Varey et al., 2008 ). ..

    Blocking Assay:

    Article Title: Overexpression of VEGF 165 b in Podocytes Reduces Glomerular Permeability
    Article Snippet: .. After blocking with 100 μl of 5% BSA in PBS for 1 hour at 37°C, 100 μl of recombinant human VEGF 165 b (R&D Systems) diluted in 1% BSA in PBS (ranging from 62.5 pg/ml to 4.0 ng/ml) or protein samples was added to each well. .. After incubation for 1 hour at 37°C with shaking and three washes, 100 μl of mouse monoclonal anti-VEGF xxx b biotinylated IgG (clone 264610/1; R&D Systems) at 0.4 μg/ml was added to each well, and the plate was left for 1 hour at 37°C with shaking.

    Sandwich ELISA:

    Article Title: Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
    Article Snippet: .. VEGF xxx b was determined with a similar sandwich ELISA, using for detection a monoclonal biotinylated mouse anti-human antibody raised against the terminal nine amino acids of VEGF 165 b (R&D Systems; clone 264610/1), and a standard curve for this assay was built with recombinant human VEGF 165 b (R&D Systems) ( Varey et al., 2008 ). ..



    Similar Products

    vegf a 165 b assay  (R&D Systems)
    93
    R&D Systems vegf a 165 b assay
    Vegf A 165 B Assay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Human+VEGF+165b+DuoSet+ELISA/pmc12133783-77-5-10
    Average 93 stars, based on 1 article reviews
    vegf a 165 b assay - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    human vascular endothelial growth factor 165  (Sino Biological)
    95
    Sino Biological human vascular endothelial growth factor 165
    Human Vascular Endothelial Growth Factor 165, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Human+VEGF+%2F+VEGFA+%2F+VEGF165+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/pm37230729-48-13-23
    Average 95 stars, based on 1 article reviews
    human vascular endothelial growth factor 165 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    vegf 165 b  (R&D Systems)
    91
    R&D Systems vegf 165 b
    Vegf 165 B, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Recombinant+Human+VEGF+165b+Protein/pmc08515680-43-0-5
    Average 91 stars, based on 1 article reviews
    vegf 165 b - by Bioz Stars, 2026-09
    91/100 stars
    		  Buy from Supplier
    vegfa 165 b  (R&D Systems)
    90
    R&D Systems vegfa 165 b
    MAPK and AKT are activated in HRMECs by VEGFA 165 a and VEGFA 165 b. A : Immunoblots of total MAPK and activated MAPK (phospho-MAPK) 10 min after treatment with VEGFA 165 a (Va), <t>VEGFA</t> <t>165</t> <t>b</t> (Vb), or media control (C). Two representative experiments are shown. B : Immunoblots of total AKT and activated AKT (phospho-AKT) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. C : Fold activation of MAPK and AKT from three immunoblotting experiments. P values are shown, t test relative to media controls (onefold).
    Vegfa 165 B, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Recombinant+Human+VEGF+165b+Protein%2C+CF/pmc08092446-81-6-12
    Average 90 stars, based on 1 article reviews
    vegfa 165 b - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    recombinant human vegf 165  (Sino Biological)
    95
    Sino Biological recombinant human vegf 165
    MAPK and AKT are activated in HRMECs by VEGFA 165 a and VEGFA 165 b. A : Immunoblots of total MAPK and activated MAPK (phospho-MAPK) 10 min after treatment with VEGFA 165 a (Va), <t>VEGFA</t> <t>165</t> <t>b</t> (Vb), or media control (C). Two representative experiments are shown. B : Immunoblots of total AKT and activated AKT (phospho-AKT) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. C : Fold activation of MAPK and AKT from three immunoblotting experiments. P values are shown, t test relative to media controls (onefold).
    Recombinant Human Vegf 165, supplied by Sino Biological, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+vegf+165+b/Human+VEGF+%2F+VEGFA+%2F+VEGF165+Protein+(His+%26+AVI+Tag)%2C+Biotinylated/us10662236-181-12-19
    Average 95 stars, based on 1 article reviews
    recombinant human vegf 165 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    MAPK and AKT are activated in HRMECs by VEGFA 165 a and VEGFA 165 b. A : Immunoblots of total MAPK and activated MAPK (phospho-MAPK) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. B : Immunoblots of total AKT and activated AKT (phospho-AKT) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. C : Fold activation of MAPK and AKT from three immunoblotting experiments. P values are shown, t test relative to media controls (onefold).

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: MAPK and AKT are activated in HRMECs by VEGFA 165 a and VEGFA 165 b. A : Immunoblots of total MAPK and activated MAPK (phospho-MAPK) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. B : Immunoblots of total AKT and activated AKT (phospho-AKT) 10 min after treatment with VEGFA 165 a (Va), VEGFA 165 b (Vb), or media control (C). Two representative experiments are shown. C : Fold activation of MAPK and AKT from three immunoblotting experiments. P values are shown, t test relative to media controls (onefold).

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Western Blot, Control, Activation Assay

    VEGFA 165 a strongly activates MAPK in primary HRMECs at doses where VEGFA 165 b has little effect. Activation of MAPK was measured with in situ immunofluorescence with a phosphospecific antibody (phospho-Thr202/Tyr204) for p44/42. A : Activation of MAPK at three time points after the addition of 1,000 pM VEGFA 165 a or VEGFA 165 b. Bar shows standard deviation. ( t test, ***p<0.001 relative to untreated control, n=8 biologic replicates.) B : Dose–response curves for activation of MAPK. The median effective dose (ED 50 ) was 73 pM for VEGFA 165 a and 1,015 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: VEGFA 165 a strongly activates MAPK in primary HRMECs at doses where VEGFA 165 b has little effect. Activation of MAPK was measured with in situ immunofluorescence with a phosphospecific antibody (phospho-Thr202/Tyr204) for p44/42. A : Activation of MAPK at three time points after the addition of 1,000 pM VEGFA 165 a or VEGFA 165 b. Bar shows standard deviation. ( t test, ***p<0.001 relative to untreated control, n=8 biologic replicates.) B : Dose–response curves for activation of MAPK. The median effective dose (ED 50 ) was 73 pM for VEGFA 165 a and 1,015 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Activation Assay, In Situ, Immunofluorescence, Standard Deviation, Control

    VEGFA 165 b is a weaker activator of AKT in primary HRMECs compared to VEGFA 165 a. A : Activation of AKT was measured with in situ immunofluorescence with a phosphospecific antibody for Ser473-AKT at five time points after the addition of 20 ng/ml (1,050 pM) VEGFA 165 a or VEGFA 165 b. Bar shows standard deviation. ( t test, ***p<0.001 relative to untreated control, n=4 biologic replicates.) B : Dose–response curves for activation of AKT. The median effective dose (ED 50 ) value for AKT activation by VEGFA 165 a was 53 pM compared to 126 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: VEGFA 165 b is a weaker activator of AKT in primary HRMECs compared to VEGFA 165 a. A : Activation of AKT was measured with in situ immunofluorescence with a phosphospecific antibody for Ser473-AKT at five time points after the addition of 20 ng/ml (1,050 pM) VEGFA 165 a or VEGFA 165 b. Bar shows standard deviation. ( t test, ***p<0.001 relative to untreated control, n=4 biologic replicates.) B : Dose–response curves for activation of AKT. The median effective dose (ED 50 ) value for AKT activation by VEGFA 165 a was 53 pM compared to 126 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Activation Assay, In Situ, Immunofluorescence, Standard Deviation, Control

    Differences in the activation of intracellular signaling between VEGFA 165 a and VEGFA 165 b in primary HRMECs begin at the receptor VEGFR2. VEGFA 165 a was a stronger activator of VEGFR2 compared to VEGFA 165 b. The median effective dose (ED 50 ) for activation by VEGFA 165 a was 254 pM compared to 1,192 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: Differences in the activation of intracellular signaling between VEGFA 165 a and VEGFA 165 b in primary HRMECs begin at the receptor VEGFR2. VEGFA 165 a was a stronger activator of VEGFR2 compared to VEGFA 165 b. The median effective dose (ED 50 ) for activation by VEGFA 165 a was 254 pM compared to 1,192 pM for VEGFA 165 b. Bars indicate the 95% confidence interval for data fit to the four-parameter log-logistic function. n=4 biologic replicates per dose.

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Activation Assay

    VEGFA 165 a has a stronger effect on leukocyte–endothelial cell adhesion gene expression in primary HRMECs than VEGFA 165 b. Relative gene expression was measured with quantitative PCR (qPCR). A : Expression of the ICAM1 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . Confluent human retinal microvascular endothelial cells (HRMECs) were treated with a saturating high dose of VEGFA 165 a or VEGFA 165 b (100 ng/ml, 5,300 pM). B : Expression of the ICAM1 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. C : Expression of the SELE gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . D : Expression of the SELE gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. E : Expression of the VCAM1 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . F : Expression of the VCAM1 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. (Triplicate assays, error bars show standard deviation. ANOVA (ANOVA): compared to media control *p<0.05, **p<0.01; compared to VEGFA 165 a † p<0.05, †† p<0.01).

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: VEGFA 165 a has a stronger effect on leukocyte–endothelial cell adhesion gene expression in primary HRMECs than VEGFA 165 b. Relative gene expression was measured with quantitative PCR (qPCR). A : Expression of the ICAM1 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . Confluent human retinal microvascular endothelial cells (HRMECs) were treated with a saturating high dose of VEGFA 165 a or VEGFA 165 b (100 ng/ml, 5,300 pM). B : Expression of the ICAM1 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. C : Expression of the SELE gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . D : Expression of the SELE gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. E : Expression of the VCAM1 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . F : Expression of the VCAM1 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. (Triplicate assays, error bars show standard deviation. ANOVA (ANOVA): compared to media control *p<0.05, **p<0.01; compared to VEGFA 165 a † p<0.05, †† p<0.01).

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Control

    VEGFA 165 a has a stronger effect on the expression of tight-junction-protein genes in primary HRMECs than VEGFA 165 b. Relative gene expression measured with quantitative PCR (qPCR). A : Expression of the CLDN5 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . Confluent human retinal microvascular endothelial cells (HRMECs) were treated with a saturating high dose of VEGFA 165 a or VEGFA 165 b (100 ng/ml, 5,300 pM). B : Expression of the CLDN5 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. C : Expression of the OCLN gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . D : Expression of the OCLN gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. (Triplicate assays, error bars show standard deviation. ANOVA (ANOVA): compared to media control *p<0.05, **p<0.01; compared to VEGFA 165 a †† p<0.01).

    Journal: Molecular Vision

    Article Title: Differences in activation of intracellular signaling in primary human retinal endothelial cells between isoforms of VEGFA 165

    doi:

    Figure Lengend Snippet: VEGFA 165 a has a stronger effect on the expression of tight-junction-protein genes in primary HRMECs than VEGFA 165 b. Relative gene expression measured with quantitative PCR (qPCR). A : Expression of the CLDN5 gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . Confluent human retinal microvascular endothelial cells (HRMECs) were treated with a saturating high dose of VEGFA 165 a or VEGFA 165 b (100 ng/ml, 5,300 pM). B : Expression of the CLDN5 gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. C : Expression of the OCLN gene at 1, 3, 6, and 24 h after treatment with VEGFA 165 . D : Expression of the OCLN gene comparing VEGFA 165 a and VEGFA 165 b at low, intermediate, and high doses measured after 6 h. (Triplicate assays, error bars show standard deviation. ANOVA (ANOVA): compared to media control *p<0.05, **p<0.01; compared to VEGFA 165 a †† p<0.01).

    Article Snippet: Recombinant human VEGFA 165 a and VEGFA 165 b were obtained from R&D Systems (Minneapolis, MN).

    Techniques: Expressing, Real-time Polymerase Chain Reaction, Standard Deviation, Control